Berlin – 15 January 2018 – KCR CFO Piotr Błoński was invited to join the recent, 36th J.P. Morgan Annual Healthcare Conference, which took place in San Francisco, U.S., last week. The conference focuses exclusively on companies defining the healthcare industry. This year was no difference: the conference gathered the top investors and industry leaders to discuss trends and strategies for the healthcare delivery systems.
“J.P. Morgan conference was a perfect occasion to discuss the market updates and challenge each other on trends and predictions for the nearest future,” said Piotr Błoński.
According to the KCR CFO, small and medium pharma will remain the fastest growing market for CROs, with a compound annual growth rate (CAGR) ~8-9 percent growth per annum for the period of 2018-2020. The largest therapeutic area will be oncology which represents approx. 30 percent of the market, with forecasted growth of 12 percent CAGR until 2020.
“As the industry moves to more and more complex studies, CROs are expected to provide innovative design solutions with an increased focus on quantitative simulations on trial feasibility, site performance analysis, and patient access,” commented Mr. Błoński.
“2018 might be another year of M&A activities, mostly due to big cash reserves of top pharma companies and tax reform in the U.S. It will remain one of the drivers for the growth of top CROs with a focus on areas like patient engagement, niche therapeutic areas, and late phase,” summarized the CFO of KCR.
KCR is a Contract Research Organization (CRO) providing clinical development solutions for the pharmaceutical, biotechnology and medical device industries. The company supports clients with full-service capabilities across three main services: Trial Execution (TE), Functional Service Provision (FS) and Late Phase (LP) over a broad range of therapeutic areas. KCR operates across four main regions: North America (NA), Western Europe (WE), Central Europe (CE) and Eastern Europe (EE) with hubs located in Boston, US, Berlin, Germany, Warsaw, Poland and Kiev, Ukraine respectively. The company’s geographical set up suits perfectly to deliver optimized trial execution strategies for life-changing therapies.
KCR: We see human behind every number
Associate Director, PR & Marketing
mobile: (+48) 605 053 164